Veracyte, Inc. (VCYT)
VCYTNASDAQ-GMMedical Specialities
$25.48
+1.32 (+5.46%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.09bn
- P/E
- 16.8
- EPS, last 4 quarters
- $1.52
- Dividend yield
- –
- Day range
- –
- 52-week range
- $21.91 to $60.91
- Average volume
- 1.67m
- Previous close
- $24.16
Analysts
8 coveringBuy6 buy, 2 hold, 0 sell
Targets a year out average $51.50, +102.1% from here
Earnings
next estimate $0.3100Next report
Dec 2025
+42.9%
Mar 2026
+60.9%
Jun 2026
+27.6%
Sep 2026
+31.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $140.64m | $139.07m | $150.32m | $151.75m |
| Gross profit | $101.97m | $101.16m | $108.55m | $107.10m |
| Operating income | $37.20m | $22.65m | $22.98m | $16.57m |
| Net income | $41.15m | $28.71m | $25.49m | $31.50m |
Last four quarters: revenue $581.78m, margin 21.8%, free cash flow $161.95m
News
8 latest- Veracyte Q3 Earnings Call Highlights Slower Growth and Added InvestmentZacks · 4 days ago
- Veracyte (VCYT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Veracyte (VCYT) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Veracyte, Inc. Reports Third Quarter 2026 Financial Results and Announces $100 Million Share Repurchase ProgramFintel · 5 days ago
- Veracyte (VCYT) Tops Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- 4 Medical Stocks With a Healthy Shot at Q3 Earnings BeatsZacks · Oct 30, 2026
- Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks · Oct 29, 2026
- Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks · Oct 28, 2026
The company
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company's molecular tests assess the unique biology of each patient's tumor to help clinicians answer essential questions about cancer care. Veracyte's Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development . The company's portfolio includes the Afirma Genomic Sequencing Classifier test , Decipher Bladder Genomic Classifier test , Decipher Prostate Genomic Classifier test , Prosigna Breast Risk of Recurrence test , and the TrueMRD Monitoring Test for MIBC .
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- veracyte.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.